🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

68,12 USD

Máx. histórico

89,55

117 días

Caída desde máximo

-23,93%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+11,89%

Cierre anterior

60,88

Rango de hoy

63,16 – 68,72

Volumen hoy

2.643.738

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,99%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 9 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
18/03/2024 29,43 29,84 28,57 29,01 -1,83% 4,32% 690.700
15/03/2024 28,79 29,92 28,71 29,55 +2,28% 4,19% 2.231.600
14/03/2024 30,36 30,36 28,25 28,89 -6,17% 6,95% 881.800
13/03/2024 31,72 32,23 30,58 30,79 -2,84% 5,20% 820.000
12/03/2024 30,63 31,74 30,11 31,69 +3,22% 5,32% 760.900
11/03/2024 31,19 31,66 30,57 30,70 -1,48% 3,49% 906.600
08/03/2024 31,34 31,65 30,55 31,16 +1,30% 3,53% 616.200
07/03/2024 31,17 31,29 30,60 30,76 -0,39% 2,20% 654.000
06/03/2024 31,87 31,90 30,18 30,88 -1,34% 5,41% 740.900
05/03/2024 30,71 31,58 30,25 31,30 +1,03% 4,33% 779.500
04/03/2024 32,71 32,77 30,08 30,98 -3,04% 8,22% 1.151.600
01/03/2024 26,50 32,91 25,40 31,95 +13,34% 28,32% 2.092.100
29/02/2024 28,87 28,94 27,79 28,19 -0,04% 3,98% 1.529.100
28/02/2024 28,18 28,92 27,98 28,20 -0,39% 3,32% 780.000
27/02/2024 28,43 28,66 27,61 28,31 +1,29% 3,69% 823.200
26/02/2024 27,02 28,46 26,84 27,95 +3,25% 6,01% 773.400
23/02/2024 26,01 27,75 25,75 27,07 +3,96% 7,71% 861.900
22/02/2024 25,82 26,61 25,52 26,04 +0,39% 4,22% 589.100
21/02/2024 25,94 26,19 25,35 25,94 -0,15% 3,24% 652.400
20/02/2024 25,71 26,36 25,31 25,98 +0,27% 4,08% 711.000
16/02/2024 25,42 26,35 25,13 25,91 +0,86% 4,80% 1.078.900
15/02/2024 25,34 25,87 25,18 25,69 +2,60% 2,72% 838.000
14/02/2024 24,34 25,38 24,29 25,04 +3,69% 4,46% 1.265.800
13/02/2024 24,85 25,10 23,58 24,15 -6,83% 6,12% 1.408.400
12/02/2024 25,69 25,97 25,43 25,92 +1,61% 2,08% 918.900
09/02/2024 25,41 25,75 25,22 25,51 +1,03% 2,09% 630.500
08/02/2024 25,31 25,67 24,88 25,25 +0,04% 3,11% 573.300
07/02/2024 26,74 26,74 25,18 25,24 -5,79% 5,83% 661.500
06/02/2024 24,95 26,89 24,69 26,79 +6,86% 8,82% 1.098.100
05/02/2024 24,78 25,18 23,94 25,07 -0,44% 5,00% 756.500